David R. McAvoy, General Counsel at Endocyte, holds 13.03K shares in Teva Pharmaceutical (Ticker: TEVA), holds 16.37K shares in Fresh Tracks Therapeutics (Ticker: FRTX), holds 0.00 shares in Endocyte (Ticker: ECYT). Most recently, David R. McAvoy Bought ― shares of Teva Pharmaceutical on Sep 09, 2025 for an estimated value of $20.98K.
What is the percentage of profitable transactions made by David R. McAvoy?
The percentage of profitable transactions made by David R. McAvoy is 0%.
What is the average return per transaction made by David R. McAvoy?
The average return per transaction made by David R. McAvoy is -60.30%.
What stocks does David R. McAvoy hold?
David R. McAvoy holds: ECYT, FRTX, TEVA stocks.
What was David R. McAvoy’s latest transaction?
David R. McAvoy latest transaction was an Informative Buy of $20.98K.
What was David R. McAvoy's most profitable transaction?
David R. McAvoy’s most profitable transaction was an Informative Buy of FRTX stock on September 21, 2020. The return on the trade was -11.60%.
What is David R. McAvoy's role in Endocyte?
David R. McAvoy's role in Endocyte is General Counsel.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.